Methylphenidate, cognition, and epilepsy: A double-blind, placebo-controlled, single-dose study.

Area of Science:

• Neurology
• Pharmacology
• Cognitive Science

Background:

• Epilepsy is frequently associated with cognitive deficits.
• Current treatments for cognitive impairment in epilepsy are limited.
• Methylphenidate (MPH) is a stimulant medication used to treat attention deficit hyperactivity disorder.

Purpose of the Study:

• To investigate the efficacy of immediate-release methylphenidate (MPH) in addressing cognitive impairments in individuals with epilepsy.
• To assess the safety and tolerability of MPH in this patient population.

Main Methods:

• A double-blind, randomized, 3-period crossover study involving patients with epilepsy and cognitive complaints.
• Participants received placebo, 10 mg MPH, and 20 mg MPH, with a 1-week interval between doses.
• Cognitive function was assessed using the Conners Continuous Performance Test 3, Symbol-Digit Modalities Test, and Medical College of Georgia Paragraph Memory Test.

Main Results:

• A statistically significant improvement in cognitive performance was observed with both 10 mg and 20 mg doses of MPH (p = 0.030 and p = 0.034, respectively).
• No increase in seizure frequency was reported with MPH administration.
• Adverse events were generally mild, including cognitive fogginess, anxiety, and tachycardia, leading to withdrawal in three participants.

Conclusions:

• Single-dose MPH shows potential for ameliorating certain cognitive deficits in patients with epilepsy.
• Further research is warranted to confirm these findings and explore long-term efficacy and safety.